Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
| Revenue (TTM) | $10.58B |
| Gross Profit (TTM) | $7.02B |
| EBITDA | $3.89B |
| Operating Margin | 30.90% |
| Return on Equity | 17.20% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $29.70 |
| Book Value | $49.31 |
| Price-to-Book | 8.63 |
| Price-to-Sales (TTM) | 13.89 |
| EV/Revenue | 13.83 |
| EV/EBITDA | 37.05 |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 23.00% |
| Shares Outstanding | $354.16M |
| Float | $352.10M |
| % Insiders | 0.51% |
| % Institutions | 89.23% |
Volatility is currently expanding
Futures are trading mixed after another tough day across Wall Street, with all the major indices crushed early on, before the Nasdaq made a late-afternoon push to wind up just modestly higher at 25,870, up 0.20%.
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
ISRG sees appendectomy as a long-term robotic growth market, but reimbursement limits near-term adoption as clinical evidence continues to build.
Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $432.83, signifying a +1.6% move from its prior day's close.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
In 2000, a “robot” mostly meant a caged arm bolted to a car line, repeating one welded seam. Most could not see, none could leave their cells unsupervised, and a full installation ran into six figures.
Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.
